Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions

IF 31 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2025-05-06 DOI:10.1038/s41574-025-01121-z

Kaipeng Zhou, Chen Lou, Po-Han Chang, Jingjing Jiang, Yue Zhao, Hsun-Ming Chang, Liangshan Mu

引用次数: 0

Abstract

Emerging pharmaceuticals that target metabolic and endocrine dysfunctions in polycystic ovary syndrome are transforming treatment paradigms. This article covers innovative drugs, including glucagon-like peptide 1 receptor agonists, sodium–glucose cotransporter 2 inhibitors, kisspeptin, neurokinin 3 receptor antagonists and artemisinins, exploring their mechanisms and potential to advance care for this disorder.

Abstract Image

查看原文本刊更多论文

有前景的多囊卵巢综合征药物：针对代谢和内分泌功能障碍

针对多囊卵巢综合征代谢和内分泌功能障碍的新兴药物正在改变治疗范式。本文涵盖了创新药物，包括胰高血糖素样肽1受体激动剂、钠-葡萄糖共转运蛋白2抑制剂、kisspeptin、神经激肽3受体拮抗剂和青蒿素，探讨了它们的机制和潜力，以促进对这种疾病的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.